Patents Examined by Nyeemah A. Grazier
  • Patent number: 10833282
    Abstract: An object is to provide a light-emitting element with high emission efficiency which includes a novel carbazole derivative that has a wide energy gap and can be used for a transport layer or a host material in a light-emitting element. A carbazole derivative in which the 4-position of dibenzothiophene or dibenzofuran is bonded to the 2- or 3-position of carbazole has been able to be provided by use of the carbazole derivative. Further, a light-emitting element having high emission efficiency has been able to be provided by use of the carbazole derivative.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 10, 2020
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Satoshi Seo, Harue Osaka, Sachiko Kawakami, Nobuharu Ohsawa, Tsuneori Suzuki, Hiromi Nowatari, Hiroki Suzuki, Kyoko Takeda
  • Patent number: 10561616
    Abstract: This invention relates to sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, and doses and methods related thereto.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: February 18, 2020
    Assignee: Incyte Corporation
    Inventors: Krishnaswamy Yeleswaram, Bhavnish Parikh, Dilip P. Modi, Trupti Sheth
  • Patent number: 10550100
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 4, 2020
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Patent number: 10414725
    Abstract: Provided herein are pyrrolomycin derivatives, which can be used to modulate Mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 17, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Kenneth Bayles, Rongshi Li, Yan Liu
  • Patent number: 10407462
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 10, 2019
    Assignee: BAR PHARMACEUTICALS S.R.L.
    Inventors: Angela Zampella, Stefano Fiorucci
  • Patent number: 10407381
    Abstract: Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: September 10, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jianjun Cheng
  • Patent number: 10406157
    Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • Patent number: 10392412
    Abstract: Disclosed herein, inter alia, are platinum-based compounds useful for treating cancer.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: August 27, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CORNELL UNIVERSITY
    Inventors: Kathleen M. Giacomini, Swati More, Sook Wah Yee, Ethan Geier, Justin Wilson
  • Patent number: 10383831
    Abstract: Compounds according to Formula I are provided: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula I.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: August 20, 2019
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: M. V. Ramana Reddy, E. Premkumar Reddy
  • Patent number: 10377720
    Abstract: A process for preparing, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]-N-hydroxy-benzenamine of formula (I) comprising: mixing 1-(4-chlorophenyl)-3-[(2 -nitrophenyl)methoxy]-1H-pyrazole of formula (II) with a nitrogen-containing base, a sulfur compound, a solvent and a platinum-based catalyst in the presence of hydrogen.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: August 13, 2019
    Assignee: Adama Makhteshim Ltd.
    Inventors: Gal Suez, Michael Grabarnick, Alexander Frenklah, Heinz Steiner
  • Patent number: 10377770
    Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 13, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Rajesh Karki, Savithri Ramurthy, Vivek Rauniyar, Richard Robinson, Patrick James Sarver
  • Patent number: 10374169
    Abstract: The present invention relates to an organic hole transport material having a compound of the structure shown in formula (I), wherein R1-R2 independently represent hydrogen, C1-C8 substituted or substituted alkyl, C2-C8 substituted or unsubstituted alkenyl, C2-C8 substituted or unsubstituted alkynyl, or C6-C10 substituted or substituted aryl, the substituents being C1-C4 alkyl or halogen. Device experiments show that the organic hole transport material of the present invention has high glass-transition temperature and high thermal stability; a hole-only organic semiconductor diode device and an organic electroluminescent device manufactured by the organic hole transport material have good hole transport performance, high and stable current efficiency, and a long device life.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 6, 2019
    Assignee: GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO. LTD
    Inventors: Kam-Hung Low, Chin-Hsin Chen, Zhe Li, Lei Dai, Lifei Cai
  • Patent number: 10370344
    Abstract: The invention provides compounds of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3); each R5 is defined as for R1; V1 is a covalent bond, —O—, or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: August 6, 2019
    Assignee: Avexxin AS
    Inventors: George Kokotos, Berit Johansen, Victoria Magrioti, Michael Tsakos
  • Patent number: 10370329
    Abstract: A process for the resolution of racemic 2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine using novel chiral salts is disclosed. An L-phenylalanine p-toluene-sulfonamide salt of (S)-2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine and a di-p-toluoyl-L-tartaric acid salt of (S)-2-(3-ethoxy-4-methoxyphenyl)-1-(methylsulphonyl)-eth-2-ylamine are also provided.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 6, 2019
    Inventors: Ramesh Dandala, Sureshbabu Jayachandra, Vipin Kumar Kaushik, Nageshwara Rao Achanta, Sivaprasad Dorasala
  • Patent number: 10364254
    Abstract: The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: July 30, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Haifeng Cui, Alan Hennessy, Qi Jin, Timothy James Miles, Stephen Frederick Moss, Neil David Pearson
  • Patent number: 10357451
    Abstract: An object of the present invention is to provide an enteral nutrition that is simply injected and suppresses gastro-esophageal reflux. The present invention provides an enteral nutrition comprising 0.1 to 1.0 mass % of alginic acid and/or sodium salt thereof, calcium, and 0.1 to 3.5 parts by mass of a chelating agent per part by mass of the calcium.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: July 23, 2019
    Assignee: SAN-EI GEN F.F.I., INC.
    Inventors: Makoto Nakauma, Sayaka Ishihara, Satomi Nakao
  • Patent number: 10351576
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: July 16, 2019
    Assignee: Novartis AG
    Inventors: Donatella Chianelli, Xiaodong Liu, Valentina Molteni, John Nelson, Jason Roland, Paul Vincent Rucker, David Charles Tully
  • Patent number: 10343984
    Abstract: The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N?-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the salt of the compound of formula (II) and a compound of formula (II) with a compound of formula (III), in the presence of a polar organic solvent; a crystalline solid form of the compound of formula (I), in particular crystalline solid form A; to a pharmaceutical composition comprising them; and to their use as a medicament, in particular to the treatment of a condition mediated by Rho-GTPase cell proteins.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: July 9, 2019
    Assignee: CHEMO RESEARCH. S.L.
    Inventor: José Amato
  • Patent number: 10344020
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: July 9, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, Grandhi Venkat Ram Krishna Mohan Gupta, John E. Macor
  • Patent number: 10329292
    Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 25, 2019
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
    Inventors: Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard